scispace - formally typeset
H

Hans Geir Eiken

Researcher at Haukeland University Hospital

Publications -  104
Citations -  3149

Hans Geir Eiken is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Population & Ursus. The author has an hindex of 33, co-authored 100 publications receiving 2961 citations. Previous affiliations of Hans Geir Eiken include Baylor College of Medicine & University of Bergen.

Papers
More filters
Journal ArticleDOI

Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure.

TL;DR: The present study demonstrates for the first time Chemokine and chemokine receptor gene expression and protein localisation in the human myocardium, introducing a new family of mediators with potentially important effects on the myocardia.
Journal ArticleDOI

Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme.

TL;DR: The recombinant hPAH, recovered in soluble forms, revealed a high specific activity even in crude extracts and was detected as a homogeneous band by Western-blot analysis using affinity-purified polyclonal rabbit anti-(rat PAH) antibodies.
Journal ArticleDOI

Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects.

TL;DR: Findings suggest that stromal cell–derived factor (SDF-1&agr;), at least in high concentrations, may mediate antiinflammatory and matrix-stabilizing effects in unstable angina and therapeutic intervention that enhances that activity could potentially be beneficial in acute coronary syndromes.
Journal ArticleDOI

Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure—modulatory effect of intravenous immunoglobulin ☆

TL;DR: The results further support a pathogenic role for chemokines in CHF and suggest that IVIg may represent a novel therapeutic approach, with the potential to improve LVEF in patients with CHF, possibly by modulatory effects on the chemokine network.
Journal ArticleDOI

Application of natural and amplification created restriction sites for the diagnosis of PKU mutations

TL;DR: PCR amplification, either conventional, or as site directed mutagenesis using primers with mismatched 3'-ends, followed by restriction endonuclease digestion, provides rapid, non-isotope assays of known mutations in the human phenylalanine hydroxylase gene.